Oncotype SEQ Liquid Select is a liquid biopsy (blood-based) mutation panel that uses next-generation sequencing (NGS) to identify and assess genomic alterations of 17 select genes in the tumors of patients with anatomic stage IIIB or IV non-small cell lung cancer (NSCLC). Designed for real-world clinical decision-making, Liquid Select distills complex NGS analysis into easy-to-interpret, actionable insights to help you tailor targeted therapy options for each patient’s unique tumor biology.
NOTE: Applications of the Liquid Select test for other anatomic stage IV solid tumors are under development. Contact Customer Service for
Why choose Liquid Select?
Historically, the majority of assays for clinically meaningful molecular alterations have relied on a tissue sample from the
tumor. However, obtaining tissue samples for lung cancer patients can be challenging. From a simple blood draw, Liquid
Select detects specific genomic alterations that can help you quickly evaluate treatment options, by focusing on genes
identified in the National Comprehensive Cancer Network (NCCN®) guideline as relevant to FDA-approved therapies
and relevant Phase II-IV clinical trials that are currently enrolling.
Liquid Select may be a good choice when:
- The patient is hard to biopsy or when the risk of biopsy may outweigh the benefit.
- Tumor tissue is not readily available, or is “quantity not sufficient” (QNS).
- Tumor tissue has been submitted for mutation testing, but the tissue test failed.
- Heterogeneity of the tumor may be important.
- Your patient is undergoing treatment but is progressing on therapy.
- A tissue surrogate is needed at disease progression, to determine evolution of tumor or for newly recurrent patients for whom testing of archival diagnostic tissue may not be relevant.
- You want to identify alternate actionable drivers to guide non-standard of care treatments.
A clinically actionable, blood-based panel for today’s treatment decisions
Unlike large blood panels used for research studies, Liquid Select is focused and designed to be immediately actionable—connecting each patient to the treatments of greatest relevance to the precise molecular biology of their tumor. Other liquid biopsy tests typically use much larger gene panels that blend “clinically actionable” and “non-clinically actionable” genes—leading to lengthy reports that highlight alterations not necessarily associated with treatment options or eligibility for clinical trials.
Liquid Select includes select genomic cancer markers that have been:
- Included in National Comprehensive Cancer Network (NCCN) guidelines*,
- Associated with sensitivity or resistance to relevant FDA-approved therapies, or
- Established as eligibility criteria for currently enrolling Phase II-IV clinical trials.
The concise, easy-to-interpret Liquid Select test report:
- Indicates whether any clinically actionable variants are present in the patient’s blood sample.
- Identifies any detected relevant variants associated with existing FDA-approved therapies or relevant clinical trials, including:
- Single nucleotide variants (SNVs).
- Copy number gain (CN gains).
- Inserts and deletions (InDels).
- Identifies actively enrolling Phase II-IV clinical trials that your patient may be eligible for on the basis of the genomic alterations identified and associated with their disease.
- Facilitates discussions with patients and other members of the care team.
Genomic Health leveraged expertise from reports issued for more than 750,000 patients in breast, colon, and prostate cancer to develop the concise, easy-to-interpret test report.
ADDITIONAL RECIPIENT FOR COLLABORATION
FOCUS ON TREATMENT PLANNING, SUITABLE FOR PATIENTS AND THEIR FAMILIES
CONCISE SUMMARY OF DETECTED ALTERATIONS
DIAGNOSIS AND STAGING PROVIDED BY ORDERING PHYSICIAN
MATCH TO TRIALS BASED ON CRITERIA MOST APPLICABLE TO PATIENT
Currently, Liquid Select is available for patients with anatomic stage IIIB or IV non-small cell lung cancer (NSCLC). Eligible patients are often diagnosed with:
- Lung adenocarcinoma.
- Lung squamous cell carcinoma (stage IV only).
- Other NSCLC (large cell carcinoma, undifferentiated, poorly differentiated, or Not Otherwise Specified (NOS)).
For patients who are pregnant or who have had a transplant, the clinical interpretation of the assay result may be affected.
Finally, patients are not eligible for Liquid Select if they have anatomic stage I, II, or IIIA solid tumors. (Stage III tumor cell-free DNA is more likely to be below the limit of detection).